(firstQuint)Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR).

 ANRS 161 L-Vir is a phase III prospective, randomized, multicenter, open-label, superiority trial for participants with low-level persistent viremia.

 Participants will be randomized with a 1:1:1 ratio to the following three arms, - Reference arm : counseling without antiretroviral treatment modification - Switch arm : switch of current PI/r for Prezista(R) (darunavir)/ Norvir(R) (ritonavir) (switch for a drug with a higher genetic barrier) 600/100 mg two times a day (BID) with counseling.

 - Addition of Isentress(R) (raltegravir) arm : Isentress(R) (raltegravir) 400 mg two times a day (BID) added to current antiretroviral treatment with counseling.

 Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)@highlight

Management of participants with low-level persistent viremia